|1.||Packer, Milton: 11 articles (10/2015 - 10/2012)|
|2.||McMurray, John J V: 11 articles (10/2015 - 10/2012)|
|3.||Solomon, Scott D: 11 articles (10/2015 - 10/2012)|
|4.||Zile, Michael R: 9 articles (10/2015 - 02/2014)|
|5.||Gong, Jianjian: 7 articles (08/2015 - 04/2010)|
|6.||Swedberg, Karl: 6 articles (10/2015 - 07/2014)|
|7.||Shi, Victor: 6 articles (08/2015 - 10/2012)|
|8.||Lefkowitz, Martin: 6 articles (08/2015 - 10/2012)|
|9.||Rouleau, Jean L: 5 articles (10/2015 - 07/2014)|
|10.||Desai, Akshay S: 5 articles (10/2015 - 07/2014)|
|1.||Hypertension (High Blood Pressure)
04/01/2014 - "In conclusion, LCZ696 is effective for the treatment of hypertension in Asian population and, in general, is safe and well tolerated. "
05/01/2015 - "One such drug, LCZ696, has shown substantial benefits in trials in hypertension and HF. "
04/01/2014 - "This randomized, double-blind, placebo-controlled study, the first in Asia for this drug, evaluated the dose-related efficacy and safety of LCZ696 in patients with hypertension using 24-hour ambulatory blood pressure (BP) monitoring. "
12/01/2015 - "LCZ696, The Need for an Indication in Arterial Hypertension."
06/01/2015 - "9C.04: TREATMENT WITH LCZ696 COMPARED TO AT1-RECEPTOR BLOCKADE IS ASSOCIATED WITH NON-SUSTAINED INCREASES OF NATRIURESIS AND DIURESIS IN ASIAN PATIENTS WITH SALT-SENSITIVE HYPERTENSION."
02/01/2015 - "The authors also discuss the results of the first randomized study PARAMOUNT investigating LCZ696 efficacy in patients with chronic heart failure and good left ventricular ejection fraction."
08/07/2015 - "LCZ696 is a novel drug not only for the treatment of heart failure but it is also likely to be a useful antihypertensive drug and may have a preferential effect on systolic pressure. "
02/14/2015 - "For the primary composite outcome of cardiovascular death or heart failure hospitalization in PARADIGM-HF, the relative risk reduction with LCZ696 vs. a putative placebo from SOLVD-T was 43% (95%CI 34–50%; P < 0.0001) with similarly large effects on cardiovascular death (34%, 21–44%; P < 0.0001) and heart failure hospitalization (49%, 39–58%; P < 0.0001). "
02/14/2015 - "A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure."
02/01/2015 - "LCZ696 : a new paradigm for the treatment of heart failure?"
|3.||Cardiovascular Diseases (Cardiovascular Disease)
07/01/2013 - "Available data show that positive efficacy and a good tolerability profile of LCZ696 in the treatment of arterial hypertension as well as preliminary data indicate that it can also be useful in the treatment of cardiovascular disease. "
04/10/2010 - "Compared with valsartan, dual-acting LCZ696 provides complementary and fully additive reduction of blood pressure, which suggests that the drug holds promise for treatment of hypertension and cardiovascular disease. "
12/01/2014 - "Inhibiting neprilysin has been a therapeutic target for several compounds that have been tested in cardiovascular disease, including ecadotril, candoxatril, omapatrilat, and LCZ696. "
|4.||Systolic Heart Failure
09/01/2015 - "PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?"
01/01/2015 - "Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice."
02/01/2015 - "PARADIGM-HF study has also shown superiority of LCZ696 compared to ACE inhibitors in stable outpatients with chronic systolic heart failure NYHA stages II and III. Therefore, LCZ696 is more effective than ACE inhibitors (and angiotensin receptor blockers). "
01/01/2015 - "The recent PARADIGM-HF trial compared the novel compound LCZ696, a combination of the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril, versus the angiotensin-converting enzyme inhibitor enalapril in 8,442 patients with symptomatic chronic systolic heart failure. "
|5.||Diastolic Heart Failure
|1.||Neprilysin (Neutral Endopeptidase)
|4.||Angiotensin Receptors (Angiotensin II Receptor)
|5.||Angiotensin Receptor Antagonists
|6.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|8.||Brain Natriuretic Peptide (Natrecor)
|9.||Biological Markers (Surrogate Marker)
|2.||Drug Therapy (Chemotherapy)
|4.||Intensive Care (Surgical Intensive Care)
|5.||Heart Transplantation (Grafting, Heart)